Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
DOI

10.1056/nejmp2106970

Type

Journal article

Journal

The New England journal of medicine

Publication Date

09/2021

Volume

385

Pages

961 - 964

Addresses

From the National Heart and Lung Institute (G.R., E.S.) and the Department of Infectious Disease (C.C.), Imperial College London; the U.K. Vaccines Taskforce (A.G.); and hVIVO Services (A.C.) - all in London; and the Department of Paediatrics, University of Oxford, Oxford, United Kingdom (H.M.).

Keywords

Humans, Antiviral Agents, Human Experimentation, Clinical Trials as Topic, COVID-19, SARS-CoV-2, COVID-19 Vaccines